search
Back to results

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (REFRESH)

Primary Purpose

Acute Schizophrenia, Schizoaffective Disorder

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
RP5063
placebo
RP5063
RP5063
aripiprazole
Sponsored by
Reviva Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Schizophrenia

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients providing informed consent prior to any study specific procedures
  • Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), or schizoaffective disorder
  • Patients with normal physical examination, laboratory, vital signs,and electrocardiogram (ECG)

Exclusion Criteria:

  • Patients with other primary psychiatric disorders as delirium, or bipolar I or II disorder

Sites / Locations

  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva Site
  • Reviva site
  • Reviva site
  • Reviva site
  • Reviva site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Active Comparator

Arm Label

15mg RP5063 daily

30mg RP5063 daily

50mg RP5063 daily

Placebo

aripiprazole

Arm Description

aripiprazole 15 mg daily

Outcomes

Primary Outcome Measures

Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score
PANSS total score comprises Positive (Delusions, Conceptual disorganization, Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness/persecution, Hostility), Negative (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking), and General Psychopathology (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance) Scales. Scores are obtained by adding the ratings of each item in each scale. Range is 7-49 for Positive and Negative scores; 16-112 for General Psychopathology score; and 30-210 for Total score. Higher score reflects worse outcome; larger reduction from baseline reflects better outcome.

Secondary Outcome Measures

Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the Clinical Global Impression Scale - Severity (CGI-S)
Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. Scores range from 1 (not ill at all) to 7 (among the most extremely ill). A reduction in score indicates an improvement in the subject's condition.
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Positive Subscale
The Positive Scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility) and is calculated by adding the subscale item scores to obtain results ranging from 7 to 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Negative Subscale
The Negative Scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking) and is calculated by adding the negative subscale item scores to obtain results ranging from 7 to 49. Minimum score is 7, maximum score is 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS General Psychopathology Subscale
The General Psychopathology Scale consists of 16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). The General Psychopathology score is obtained by adding the ratings of each item in the scale, with results ranging from 16 to 112. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.

Full Information

First Posted
December 7, 2011
Last Updated
January 20, 2015
Sponsor
Reviva Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01490086
Brief Title
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Acronym
REFRESH
Official Title
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Reviva Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Schizophrenia, Schizoaffective Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
234 (Actual)

8. Arms, Groups, and Interventions

Arm Title
15mg RP5063 daily
Arm Type
Experimental
Arm Title
30mg RP5063 daily
Arm Type
Experimental
Arm Title
50mg RP5063 daily
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
aripiprazole
Arm Type
Active Comparator
Arm Description
aripiprazole 15 mg daily
Intervention Type
Drug
Intervention Name(s)
RP5063
Intervention Description
daily
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
daily
Intervention Type
Drug
Intervention Name(s)
RP5063
Intervention Description
daily
Intervention Type
Drug
Intervention Name(s)
RP5063
Intervention Description
daily
Intervention Type
Drug
Intervention Name(s)
aripiprazole
Intervention Description
daily
Primary Outcome Measure Information:
Title
Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score
Description
PANSS total score comprises Positive (Delusions, Conceptual disorganization, Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness/persecution, Hostility), Negative (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking), and General Psychopathology (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance) Scales. Scores are obtained by adding the ratings of each item in each scale. Range is 7-49 for Positive and Negative scores; 16-112 for General Psychopathology score; and 30-210 for Total score. Higher score reflects worse outcome; larger reduction from baseline reflects better outcome.
Time Frame
Baseline to Day 28
Secondary Outcome Measure Information:
Title
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the Clinical Global Impression Scale - Severity (CGI-S)
Description
Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. Scores range from 1 (not ill at all) to 7 (among the most extremely ill). A reduction in score indicates an improvement in the subject's condition.
Time Frame
Baseline to Day 28
Title
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Positive Subscale
Description
The Positive Scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility) and is calculated by adding the subscale item scores to obtain results ranging from 7 to 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
Time Frame
Baseline to Day 28
Title
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Negative Subscale
Description
The Negative Scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking) and is calculated by adding the negative subscale item scores to obtain results ranging from 7 to 49. Minimum score is 7, maximum score is 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
Time Frame
Baseline to Day 28
Title
Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS General Psychopathology Subscale
Description
The General Psychopathology Scale consists of 16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). The General Psychopathology score is obtained by adding the ratings of each item in the scale, with results ranging from 16 to 112. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
Time Frame
Baseline to Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients providing informed consent prior to any study specific procedures Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), or schizoaffective disorder Patients with normal physical examination, laboratory, vital signs,and electrocardiogram (ECG) Exclusion Criteria: Patients with other primary psychiatric disorders as delirium, or bipolar I or II disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M Cantillon
Organizational Affiliation
Fundacion REVIVA, Red de VIH del Valle del Cauca
Official's Role
Study Director
Facility Information:
Facility Name
Reviva site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19039
Country
United States
Facility Name
Reviva site
City
Bangalore
Country
India
Facility Name
Reviva site
City
Chennai
Country
India
Facility Name
Reviva site
City
Guntur
Country
India
Facility Name
Reviva site
City
Jaipur
Country
India
Facility Name
Reviva site
City
Kanpur
Country
India
Facility Name
Reviva site
City
Lucknow
Country
India
Facility Name
Reviva site
City
Mangalore
Country
India
Facility Name
Reviva site
City
Bahru
Country
Malaysia
Facility Name
Reviva site
City
Johor
Country
Malaysia
Facility Name
Reviva site
City
KLumpur
Country
Malaysia
Facility Name
Reviva Site
City
Ridzuan
Country
Malaysia
Facility Name
Reviva site
City
Kisinau
Country
Moldova, Republic of
Facility Name
Reviva site
City
Mandaluyon
Country
Philippines
Facility Name
Reviva site
City
Mandurriao
Country
Philippines
Facility Name
Reviva site
City
Subangdaku
Country
Philippines

12. IPD Sharing Statement

Learn more about this trial

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

We'll reach out to this number within 24 hrs